Earnings Call Summary | Azenta(AZTA.US) Q3 2024 Earnings Conference
Earnings Call Summary | Azenta(AZTA.US) Q3 2024 Earnings Conference
Operating profit reached $4.6 million, the first in six quarters, reflecting efficient execution and profitability strategies.The following is a summary of the Azenta, Inc. (AZTA) Q3 2024 Earnings Call Transcript:
以下是Azenta, Inc. (AZTA) 2024年Q3業績會交流摘要:
Financial Performance:
金融業績：
Azenta reported Q3 2024 revenue of $173 million, up 5% year-over-year and 9% sequentially.
Adjusted EBITDA margin was 10.3%, marking an improvement of 260 basis points year-over-year and 440 basis points versus the prior quarter.
Operating profit reached $4.6 million, the first in six quarters, reflecting efficient execution and profitability strategies.
Non-GAAP EPS for the quarter was $0.16.
Azenta報告Q3 2024年營業收入爲17300萬美元，同比增長5%，環比增長9%。
調整後的EBITDA利潤率爲10.3%，同比提高260個點子，較上一季度提高440個點子。
營業利潤達460萬美元，爲六個季度以來首次，反映出有效的執行和盈利策略。
本季度非GAAP每股收益爲0.16美元。
Business Progress:
業務進展：
Azenta is focusing on automating sample management with new tools for faster and cheaper registration and storage, enhancing operational efficiencies and customer satisfaction.
Multi-year contracts for managing large sample collections for pharmaceutical companies are underway, signifying robust business prospects.
The company is advancing in the Multiomics GENEWIZ team with strong performances and significant volume growth in next-generation sequencing, despite broader market challenges.
Azenta專注於使用新工具自動化樣品管理，以實現更快、更便宜的註冊和存儲，提高運營效率和客戶滿意度。
針對藥品公司管理大型樣品收藏的多年合同正在進行中，標誌着業務前景強勁。
儘管市場面臨更廣泛的挑戰，但該公司在Multiomics GENEWIZ團隊中表現強勁，下一代測序的利潤和規模穩步增長。
Opportunities:
機會：
Azenta plans to further enhance its sample management capabilities, aiming to become a comprehensive provider for laboratory and AI model inputs.
Significant interest in rare and valuable samples presents opportunities for expanded service offerings and leveraging advanced technology.
Azenta計劃進一步提高其樣品管理能力，力爭成爲實驗室和人工智能模型輸入的全面提供商。
對罕見和有價值樣品的顯著興趣爲拓展服務提供了機會，藉助先進技術實現價值提升。
More details: Azenta IR
更多詳情請參考Azenta投資關係(IR)公司網站。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。